A. C. Tan, A. B. Heimberger, and M. Khasraw, Immune Checkpoint Inhibitors in Gliomas, Curr. Oncol. Rep, vol.19, p.23, 2017.

T. H. Schaller and J. H. Sampson, Advances and challenges: dendritic cell vaccination strategies for glioblastoma, Expert Rev. Vaccines, vol.16, pp.27-36, 2017.

C. Martin, Oncolytic Viruses: Treatment and Implications for Patients With Gliomas, Clin. J. Oncol. Nurs, vol.21, issue.2, pp.60-64, 2017.

M. Cheray, R. Pacaud, A. Nadaradjane, L. Oliver, F. M. Vallette et al., Specific Inhibition of DNMT3A/ISGF3g Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth, Theranostics, vol.6, pp.1988-1999, 2016.

M. Cheray, A. Nadaradjane, P. Bonnet, S. Routier, F. M. Vallette et al., Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness, Epigenomics, vol.6, pp.267-275, 2014.

M. Cheray, R. Pacaud, A. Nadaradjane, F. M. Vallette, C. et al., Specific inhibition of one DNMT1-including complex influences tumor initiation and progression, Clin. Epigenetics, vol.5, p.9, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00851207

B. K. Ahir, H. Ozer, H. H. Engelhard, and S. S. Lakka, MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review, Crit. Rev. Oncol. Hematol, vol.120, pp.22-33, 2017.

A. Shea, V. Harish, Z. Afzal, J. Chijioke, H. Kedir et al., MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics, Cancer Med, vol.5, pp.1917-1946, 2016.

L. Chen and C. Kang, miRNA interventions serve as 'magic bullets' in the reversal of glioblastoma hallmarks, Oncotarget, vol.6, pp.38628-38642, 2015.

N. Mercatelli, S. Galardi, and S. A. Ciafrè, MicroRNAs as Multifaceted Players in Glioblastoma Multiforme, Int. Rev. Cell Mol. Biol, vol.333, pp.269-323, 2017.

Y. Gao, X. Chen, and H. Liu, Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression, Sci. Rep, vol.6, p.32972, 2016.

J. Lin, S. Teo, D. H. Lam, K. Jeyaseelan, W. et al., MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme, Cell Death Dis, vol.3, p.398, 2012.

J. Hayes, H. Thygesen, C. Tumilson, A. Droop, M. Boissinot et al., Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature, Mol. Oncol, vol.9, pp.704-714, 2015.

R. Li, K. Gao, H. Luo, X. Wang, Y. Shi et al., Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma, J. Exp. Clin. Cancer Res, vol.33, p.9, 2014.

X. Pan, L. Huang, W. , and X. , MiR-370 functions as prognostic marker in patients with hepatocellular carcinoma, Eur. Rev. Med. Pharmacol. Sci, vol.21, pp.3581-3585, 2017.

X. Lin, Z. Wang, Y. Wang, and W. Feng, Serum MicroRNA-370 as a potential diagnostic and prognostic biomarker for pediatric acute myeloid leukemia, Int. J. Clin. Exp. Pathol, vol.8, pp.14658-14666, 2015.

H. Liu, N. Yang, Z. Fei, J. Qiu, D. Ma et al., Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease, Biomed. Rep, vol.5, pp.332-336, 2016.

W. Gao, H. W. He, Z. M. Wang, H. Zhao, X. Q. Lian et al., Plasma levels of lipometabolismrelated miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease, Lipids Health Dis, vol.11, p.55, 2012.

X. Liu, Y. G. Huang, C. G. Jin, Y. C. Zhou, X. Q. Chen et al., MicroRNA-370 inhibits the growth and metastasis of lung cancer by down-regulating epidermal growth factor receptor expression, Oncotarget, vol.8, pp.88139-88151, 2017.

X. Zhang, J. Zeng, M. Zhou, B. Li, Y. Zhang et al., The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia, Mol. Cancer, vol.11, p.56, 2012.

W. Yungang, L. Xiaoyu, T. Pang, L. Wenming, and X. Pan, miR-370 targeted FoxM1 functions as a tumor suppressor in laryngeal squamous cell carcinoma (LSCC), Biomed. Pharmacother, vol.68, pp.149-154, 2014.

S. Lo, P. S. Hung, J. H. Chen, H. F. Tu, W. L. Fang et al., Overexpression of miR-370 and downregulation of its novel target TGFb-RII contribute to the progression of gastric carcinoma, Oncogene, vol.31, pp.226-237, 2012.

S. Wei, M. , and W. , MiR-370 functions as oncogene in melanoma by direct targeting pyruvate dehydrogenase B, Biomed. Pharmacother, vol.90, pp.278-286, 2017.

D. Nandi, P. S. Cheema, N. Jaiswal, and A. Nag, FoxM1: Repurposing an oncogene as a biomarker, Semin. Cancer Biol, vol.52, pp.74-84, 2017.

Y. Kang, J. M. Mariano, J. Angdisen, T. W. Moody, B. A. Diwan et al., Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1, Mol. Carcinog, vol.29, pp.112-126, 2000.

V. W. Van-beusechem, J. Grill, D. C. Mastenbroek, T. J. Wickham, P. W. Roelvink et al., Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished, J. Virol, vol.76, pp.2753-2762, 2002.